Dr Kenny Simmen
Vice President, Scientific Innovation, Janssen Infectious Diseases & Vaccines
Based in the UK, Kenny Simmen is currently the Vice President, Scientific Innovation, Janssen Infectious Diseases & Vaccines. He leads the identification of novel science and drug / vaccine opportunities through the J&J Innovation Centers worldwide. He has been in J&J since 1997, working in California, Belgium and the UK. From 2002-2015 in Tibotec then Janssen he built and then led a global Research and Early Development team which successfully identified and advanced compounds from the bench up to the clinical “proof-of-concept”, particularly for hepatitis C, including Simeprevir, an FDA approved protease inhibitor (Olysio®) developed together with Medivir. He has worked on discovery and development programs in HIV, HBV, dengue, influenza, RSV and other respiratory infections.
Kenny is also the Janssen representative on the EFPIA InnoMedStrategy (InnoMEDS) Group and IMI Strategic Governing Group (SGG) Infection Control.
Dr. Simmen holds an B.Sc.(Hons) degree in Molecular Biology from the University of Edinburgh (1988), and obtained his Ph.D. at the European Molecular Biology Laboratory (EMBL), Heidelberg (1992). Following postdoctoral research at the Netherlands Cancer Institute, Dr. Simmen worked in the Virology Department at the Roche Research Centre in Welwyn Garden City, UK.